|
|
|
501-1,000 employees
View all
|
|
pharmaceuticals
|
|
29 Market Street,Maidenhead,SL6,United Kingdom
|
|
Seqirus, part of the CSL Group, is the new global company created from the combined strength and expertise of bioCSL and the influenza vaccines business formerly owned by Novartis. In July 2015, the two businesses joined forces to create Seqirus, now the second largest influenza vaccine company in the world. With extensive research and production expertise and manufacturing plants in the US, UK, Germany and Australia, Seqirus is a transcontinental partner in pandemic preparedness and a major contributor to the prevention and control of influenza globally. Seqirus has a workforce of over 2,000 employees, significant manufacturing capacity and a commercial presence in over 20 countries. In Australia and New Zealand, Seqirus markets a comprehensive range of vaccines and speciality pharmaceutical products. It also manufactures products of national significance for Australia, including antivenoms and Q fever vaccine.
|
Seqirus Email Formats | Example Email Formats | Percentage |
---|---|---|
{first}.{last} | [email protected] |
100%
|
The widely used Seqirus email format is {first}.{last} (e.g. [email protected]) with 100% adoption across the company.
To contact Seqirus customer service number in your country click here to find.
Find accurate personal emails, work emails and phone numbers for employees
Accelerate prospecting with instant access to 300M professionals from 30M companies with the right contact details.